Inhaled Anticholinergics for Chronic Obstructive Pulmonary Disease in the Elderly

Zoe Antonia Kopsaftis1,2 and Kristin Veronica Carson1,3
1School of Medicine, The University of Adelaide, South Australia, Australia
2Respiratory Medicine, The Queen Elizabeth Hospital, South Australia, Australia
3Clinical Practice Unit, The Basil Hetzel Institute for Translational Health Research, South Australia, Australia

Chronic obstructive pulmonary disease (COPD) has an estimated prevalence of 15% among people aged above 65 years [1]. While morbidity is considered to increase with age, it is also hypothesised that this could be further enhanced by associated comorbid conditions including cardiovascular disease and diabetes [2-4]. COPD usually occurs as a result of exposure to smoking or other noxious particles in combination with genetic predisposition [3]. Subsequent chronic inflammatory processes in the lungs result in loss of elasticity and plugging of the small airways as well as parenchymal destruction [5]. A novel treatment which would slow the progression of lung function decline associated with age and COPD is desirable and of increasing interest [8]. Hence, currently inhaled bronchodilators are, a staple of management of the occurrence and prevention of COPD [3]. These are separated into long and short acting depending on their duration of effectiveness. Within these groups are beta-2 agonist and anticholinergic agents, which may be given either as mono or combination therapy.

Anticholinergic agents work by binding to muscarinic receptors in the lung to inhibit the contraction initiated by acetylcholine expressed via the cholinergic nerves [9]. However, muscarinic receptors are not localised to the lungs and anticholinergic effects may result in adverse effects, with increased risk to elderly and frail patients. Anticholinergic drugs have wider applications than simply inhaled forms for respiratory effects, with increased risk to elderly and frail patients. Anticholinergic via the cholinergic nerves [9]. However, muscarinic receptors are not

well as anti-ulcer and diarrhoea drugs [10]. Figure 1 demonstrates potential anticholinergic adverse effects and how they may manifest in severity.

Anticholinergic agents are recommended for management of stable and exacerbations of COPD [3,8]. However, considering their association with adverse events which may have heightened risk to elderly and frail patients, the necessity of their addition to treatment plans should be further assessed. Given the burden of anticholinergic drugs likely to be consumed by elderly people on a daily basis, it may be desirable to eliminate their use where possible, thus, the necessity of inhaled anticholinergics for the management of COPD in the elderly should be further investigated.

References

*Corresponding author: Zoe Antonia Kopsaftis, Level 4A, 28 Woodville Road, Woodville South, South Australia, Australia, Tel: 61882228685; Fax: 61883034401; E-mail: Zoe.Kopsaftis@sa.gov.au

Received November 03, 2015; Accepted December 01, 2015; Published December 08, 2015


Copyright: © 2015 KopsaftisZA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.